SCHEMBL590197

SCHEMBL590197

NCC1CN(c2ccc3c(c2)NC(=O)CO3)C(=O)O1

nearest known ligand 0.52

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
KMT2A Q03164 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
F10 P00742 1/20 0.50
NR3C2 P08235 4/20 0.46
DRD4 P21917 5/20 0.45
DRD2 P14416 4/20 0.45
DRD3 P35462 3/20 0.45
PARP1 P09874 1/20 0.45
MMP12 P39900 1/20 0.45
MAPT P10636 2/20 0.42
HPGD P15428 1/20 0.41
TRPV1 Q8NER1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL591143 1.00 ALDH1A1 (0.52) ALDH1A1KMT2ASMN1; SMN2NPSR1F10
SCHEMBL16179910 0.91 ALDH1A1 (0.50) ALDH1A1KMT2ASMN1; SMN2NPSR1F10
SCHEMBL591583 0.91 ALDH1A1 (0.50) ALDH1A1KMT2ASMN1; SMN2NPSR1F10
SCHEMBL591862 0.89 ALDH1A1 (0.48) ALDH1A1KMT2ASMN1; SMN2NPSR1NR3C2
SCHEMBL591558 0.89 ALDH1A1 (0.48) ALDH1A1KMT2ASMN1; SMN2NPSR1NR3C2
SCHEMBL591559 0.89 ALDH1A1 (0.48) ALDH1A1KMT2ASMN1; SMN2NPSR1NR3C2
SCHEMBL592012 0.88 ALDH1A1 (0.52) ALDH1A1KMT2ASMN1; SMN2NPSR1NR3C2
SCHEMBL592011 0.88 ALDH1A1 (0.52) ALDH1A1KMT2ASMN1; SMN2NPSR1NR3C2
SCHEMBL1845036 0.87 ALDH1A1 (0.51) ALDH1A1KMT2ASMN1; SMN2NPSR1NR3C2
SCHEMBL1845035 0.87 ALDH1A1 (0.51) ALDH1A1KMT2ASMN1; SMN2NPSR1NR3C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2146987-B1 OXAZOLIDINONE ANTIBIOTIC DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2015-12-02 EP disclosed
US-8114867-B2 Oxazolidinone antibiotic derivatives ACTELION PHARMACEUTICALS LTD (CH) 2012-02-14 US disclosed
US-20100137290-A1 OXAZOLIDINONE ANTIBIOTIC DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-06-03 US disclosed
EP-2146987-A2 OXAZOLIDINONE ANTIBIOTIC DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-01-27 EP disclosed
WO-2008126024-A2 OXAZOLIDINONE ANTIBIOTIC DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137290-A1 OXAZOLIDINONE ANTIBIOTIC DERIVATIVES OXA1L, XDH, CCNY ALDH1A1 1130/4885KMT2A 3898/4885SMN1; SMN2 2745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.